4 results
The primary objective is to assess whether RDN by other devices than Medtronic added to usual care compared to usual care alone reduces BP in subjects, classified as non-responders on renal denervation, six months after RDN.
The objective is to assess the feasibility and safety of the Qvanteq*s bioactive coronary Qstent for treatment of stable coronary artery disease patients with de novo coronary artery stenosis in native vessels.
To increase progression-free survival at 3 months.
The primary objective is to assess whether RD added to usual care compared to usual care alone reduces BP (24-h or average day-time SBP as determined with the use of ambulatory BP monitoring (ABPM)) in subjects with an average mean day-time SBP of…